TheEdgeResearch
Home / Stocks / HOFBF

Hofseth BioCare ASA (HOFBF)

OTC Consumer Defensive Packaged Foods
$0.12 ▲ +0.00%
Market Cap
$48.6M
Sector
Consumer Defensive
Industry
Packaged Foods
Beta
0.26
52-Wk Range
0.1183-0.176
CEO
Jon Olav Odegard
Country
NO
Currency
USD

Hofseth BioCare ASA operates in the Packaged Foods industry of the Consumer Defensive sector, headquartered in Ålesund, MR, NO. The stock last traded at $0.12, up 0.00% on the session, giving a market capitalisation of $48.6M. On trailing twelve-month figures it carries a trailing P/E of -3.50, a net margin of -45.7%. Its beta of 0.26 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.50
Price / Sales
1.58
Price / Book
-291.05
EV / EBITDA
-13.20
Gross margin
-8.0%
Operating margin
-33.9%
Net margin
-45.7%
Return on equity
—
Debt / equity
-158.89
Current ratio
0.96
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
84
IPO date
2018-08-22
Headquarters
Ålesund, MR, NO
About Hofseth BioCare ASA

Hofseth BioCare ASA, an international firm based in Norway, specializes in developing and supplying premium biomarine ingredients for both human and animal health. The company's product portfolio features various specialized offerings, including Brilliant salmon oil and OmeGo salmon oil, which promotes healthy cholesterol levels and supports cardiovascular well-being. ProGo, a salmon protein hydrolysate, serves as a rapidly assimilated protein supplement. For skeletal and joint health, Hofseth offers CalGo, a marine calcium powder. CollaGo, a collagen peptide powder, is designed to improve the appearance of hair, skin, and nails. Additionally, PetGo provides a non-soluble protein formulation. Distribution of these products is managed through a multi-channel approach, utilizing a network of distributors, agents, and its dedicated internal sales team. Hofseth BioCare also holds a significant research collaboration with Stanford University School of Medicine, focusing on pre-clinical and clinical studies related to conditions such as necrotizing enterocolitis and irritable bowel syndrome. Established in 2000, the company's main operations are based in Ålesund, Norway.

Comparable companies

Hofseth BioCare ASA is most often compared with the following Consumer Defensive names:

AURXBXPHFHLTRFIPHYFKNTPFMLLCFPBIGFPOLBFSCNLFVTIAF
More research on HOFBF
HOFBF technical analysis HOFBF TheEdge Score Compare against peers
Open full interactive analysis & DCF →